Published in Haemostasis on January 01, 1991
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well? Curr Cardiol Rev (2010) 0.80
Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits. J Clin Invest (1996) 0.79
Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res (2006) 0.76
Homology modeling and structural validation of tissue factor pathway inhibitor. Bioinformation (2013) 0.75
Why does the blood not coagulate? West J Med (1993) 0.75
[Venous thromboembolism--incidence and risk factors in Oslo]. Tidsskr Nor Laegeforen (1998) 2.03
Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med (2006) 2.02
Antithrombin (heparin cofactor) assay with "new" chromogenic substrates (S-2238 and Chromozym TH). Thromb Res (1977) 1.46
Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res (1988) 1.43
Adverse effect of warfarin in acute myocardial infarction: increased left ventricular thrombus formation in patients not treated with high-dose heparin. Eur Heart J (1993) 1.42
Heparin cofactor activity measured with an amidolytic method. Thromb Res (1975) 1.42
The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res (1976) 1.41
[Alcohol abuse as the cause of admission to a medical department]. Tidsskr Nor Laegeforen (1990) 1.39
Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol (1966) 1.26
Immunological studies on human antithrombin 3. Influence of age, sex and use of oral contraceptives on serum concentration. Scand J Haematol (1970) 1.22
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med (2001) 1.21
Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma. Scand J Clin Lab Invest (1970) 1.21
Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res (1976) 1.18
Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action. J Biol Chem (1996) 1.18
Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol (1989) 1.16
Bed rest and increased diuretic treatment in chronic congestive heart failure. Eur Heart J (1985) 1.14
Binding of thrombin to antithrombin III. Scand J Clin Lab Invest (1969) 1.12
The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl (1979) 1.07
Anticoagulant activity of heparin: assay of bovine, human and porcine preparations by amidolytic and clotting methods. Thromb Res (1977) 1.06
Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest (1968) 1.06
Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res (1978) 1.03
Assay of progressive antithrombin in plasma. Thromb Diath Haemorrh (1970) 1.02
The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res (1989) 0.98
The effect of antithrombin III on the activity of the coagulation factors VII, IX and X. Thromb Haemost (1976) 0.98
Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther (1988) 0.98
Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest (1982) 0.97
Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest (1992) 0.95
Molar antithrombin concentration in normal human plasma. Haemostasis (1983) 0.95
Antifactor Xa activity measured with amidolytic methods. Haemostasis (1976) 0.93
Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol (1998) 0.92
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol (1990) 0.92
Oral contraceptives and low antithrombin-3 concentration. Lancet (1970) 0.92
Inhibition of the thrombin-fibrinogen reaction by heparin and purified cofactor. Scand J Haematol (1968) 0.92
Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis (1978) 0.92
Changes in antithrombin 3 levels following cessation of anticoagulant therapy. Acta Med Scand (1973) 0.91
Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis (1989) 0.91
Recurrent endocarditis in silver-coated heart valve prosthesis. J Heart Valve Dis (1999) 0.90
Antifactor Xa activity in thrombophilia. Studies in a family with Ar-III deficiency. Scand J Haematol (1977) 0.90
Low levels of plasminogen in cerebrospinal fluid after intraventricular haemorrhage: a limiting factor for clot lysis? Acta Paediatr (1995) 0.90
Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis (1991) 0.89
Antithrombin-3 concentration and ABO blood-groups. Lancet (1971) 0.89
Antithrombin 3. Protection against death after injection of thromboplastin. Science (1969) 0.89
Platelet aggregation induced by ADP from unsheared erythrocytes at physiological Ca++-concentration. Br J Haematol (1981) 0.89
Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand (1988) 0.89
The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis (1992) 0.88
Biological action and clinical significance of antithrombin III. Haematologia (Budap) (1984) 0.88
Separation and characterization of two fibrinolytic inhibitors from human placenta. Thromb Diath Haemorrh (1971) 0.88
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol (1997) 0.87
Studies on soluble fibrin in plasma. I. N-terminal analysis of a modified fraction I (Cohn) from normal and thrombin-incubated plasma. Scand J Clin Lab Invest (1971) 0.87
Inhibition of the thrombin-fibrinogen reaction by heparin in the absence of cofactor. Scand J Haematol (1968) 0.86
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol (1993) 0.86
A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res (1987) 0.86
Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid. Eur J Pediatr (1996) 0.86
Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis (1986) 0.85
Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit? J Intern Med (1995) 0.85
Heparin cofactor IIOslo. Mutation of Arg-189 to His decreases the affinity for dermatan sulfate. J Biol Chem (1989) 0.85
Protein C: a simplified semi-automated activity assay. Thromb Res (1986) 0.84
Major operations, hemostatic parameters and venous thrombosis. Thromb Res (1974) 0.84
A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost (1990) 0.83
Increased plasma thrombomodulin in cancer patients. Thromb Haemost (1993) 0.83
Atrial fibrillation and left atrial enlargement: cause or effect? J Intern Med (1991) 0.83
N-terminal analysis during coagulation of purified human fibrinogen, fraction I, and plasma. Scand J Clin Lab Invest (1965) 0.82
Sequelae to genital trauma in torture victims. Arch Androl (1983) 0.82
High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand (1989) 0.82
Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Ren Physiol (1986) 0.82
Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res (1984) 0.82
On-pump versus off-pump coronary artery bypass: independent risk factors and off-pump graft patency. Eur J Cardiothorac Surg (2001) 0.82
Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res (1996) 0.82
Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost (1988) 0.82
Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis (1991) 0.82
Low antithrombin III in acute hepatic failure at term. Scand J Haematol (1982) 0.82
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost (1998) 0.81
Functional and histopathological changes in dog kidneys after administration of cisplatin. Ren Physiol (1987) 0.81
The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond) (1994) 0.81
Acceleration of fibrin polymerization by dextran and ficoll. Interaction with calcium and plasma proteins. Scand J Clin Lab Invest (1966) 0.81
Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris. J Cardiovasc Pharmacol (1989) 0.81
[The ethanol test--a sensitive indicator of intravascular coagulation]. Ginekol Pol (1970) 0.80
Simplified assay for antithrombin III activity using chromogenic peptide substrate. Manual and automated method. Scand J Haematol (1983) 0.80
Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. Thromb Res (1996) 0.80
Renal vascular adjustments to partial renal venous obstruction in dog kidney. Circ Res (1987) 0.80
Intraventricular streptokinase increases cerebrospinal fluid D dimer in preterm infants with posthaemorrhagic ventricular dilatation. Acta Paediatr (1994) 0.79
Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost (1985) 0.79
Effect of cisplatin on renal haemodynamics and tubular function in the dog kidney. Int J Androl (1987) 0.79
Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb (1991) 0.79
Lipoprotein(a), other lipoproteins and hemostatic profiles in patients with ischemic stroke: the relation to cardiogenic embolism. Cerebrovasc Dis (2000) 0.79
Inactivation of bovine and human thrombin and factor Xa by antithrombin III studied with amidolytic methods. Thromb Res (1977) 0.79
Ethanol gelation and fibrin monomers in plasma. Scand J Haematol Suppl (1971) 0.79
Inhibition of the thrombin-fibrinogen reaction by alpha2-macroglobulin, studied by N-terminal analysis. Thromb Diath Haemorrh (1969) 0.79
Chronic organic psycho-syndrome in Greek torture victims. Dan Med Bull (1984) 0.78
Histological staining properties of in vitro formed fibrin clots and precipitated fibrinogen. Acta Pathol Microbiol Scand (1969) 0.78
Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res Suppl (1991) 0.78
Predictive value of coagulation markers concerning clinical outcome 90 days after anterior myocardial infarction. Thromb Haemost (1999) 0.78
Psychological and physical long-term effects of torture. A follow-up examination of 22 Greek persons exposed to torture 1967-1974. Scand J Soc Med (1985) 0.78
Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight heparin. Acta Obstet Gynecol Scand (1992) 0.78
Isolation and characterization of heparin from human mastocytoma tissue. Thromb Haemost (1980) 0.77
Heparin cofactor II activity in plasma: application of an automated assay method to the study of a normal adult population. Scand J Haematol (1986) 0.77